BREAKING
Juno Therapeutics Inc (NASDAQ:JUNO) and Kite Pharma (NASDAQ:KITE) stocks are popping in after hours after the FDA has removed a clinical hold.

STORY
After hours on July 7th Juno Therapeutics Inc (NASDAQ:JUNO) stock collapsed on news that two patients died during Phase II clinical trial of JCAR01. The FDA placed a clinical hold on the entire trial and the worst case scenario was at least tangible, though unlikely -- a total end to JUNO's CAR-T trial for adult leukemia patients.


But news after the close just broke that the FDA has removed the clinical hold from Juno Therapeutics and it will restart, just a week after the initial news broke. Juno Therapeutics Inc (NASDAQ:JUNO) stock is printing much higher in the after-hours trade, hitting $35.80 as of this writing, up from the closing price of $27.79.



We have highlighted the after-hours price for JUNO in yellow.

Under the revised protocol, the trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.

We do note that Juno Therapeutics Inc (NASDAQ:JUNO) stock closed at $40.82 on July 7th, the last price before the FDA placed a clinical hold on the trial. Kite Pharma Inc (NASDAQ:KITE), the other hotly watched CAR-T oncology biotech stock fell with the initial news from JUNO on July 7th from $52.10 to a close today of $46.96. Now that Juno Therapeutics Inc has received the green light to restart the trial, Kite Pharma (NASDAQ:KITE) stock is also popping after hours to $52.49.



We have highlighted the after-hours price for Kite Pharma Inc (NASDAQ:KITE) in yellow.

For now, the scare that CAR-T was doomed to fail seems to have lifted, and JUNO and KITE are back to business as normal. Such is the world of (essentially) zero revenue biotechnology stocks in the field of oncology.

WHY THIS MATTERS
At CML we identify the revolutionary thematic transformations that are coming and then the companies that will benefit most from them to find the "next Apple" or the "next Google." Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution. Our purpose is to break the information monopoly held by the top .1%.

Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, drones, biotech and more. In fact, here are just two of the trends that will radically affect the future that we are ahead of:



The Internet of Things (IoT) market will be measured in trillions of dollars as of next year. CML Pro has named the top two companies that will benefit. Then there's cyber security:



Market correction or not, recession or not, the growth in this area is a near certainty, even if projections come down, this is happening. CML Pro has named the single best cyber security stock to benefit from this theme.

These are just two of the themes we have identified and this is just one of the fantastic reports CML Pro members get along with all the visual tools, the precious few thematic top picks for 2016, research dossiers and alerts. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.